Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Cipher Pharmaceuticals Inc T.CPH

Alternate Symbol(s):  CPHRF

Cipher Pharmaceuticals Inc. is a specialty pharmaceutical company with a diversified portfolio of commercial and early to late-stage products, mainly in dermatology. The Company acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products in Canada, the United States, and South America. Its dermatology products include Actikerall, Epuris, and Vaniqa. Its hospital acute care products include Aggrastat and Brinavess. Its out-licensed products include Absorica, ConZip and Lipofen. Durela is its specialty medicine. Its product pipeline includes MOB-015, CF-101, and DTR-001. It delivers novel products to healthcare professionals and patients in Canada in a range of therapeutic areas, including dermatology, women’s health, urology and others. It also has the Natroba operations and global product rights to Natroba and its authorized generic Spinosad, a topical treatment for both head lice and scabies.


TSX:CPH - Post by User

Comment by Northforce13on Feb 25, 2021 10:20am
103 Views
Post# 32657182

RE:RE:RE:RE:Debt-Free CPH: At 1.5 times its 2020 EBITDA And The Buyback

RE:RE:RE:RE:Debt-Free CPH: At 1.5 times its 2020 EBITDA And The BuybackIt's always amusing to post something negative about a stock and watch some longs come out in a panic with rose colored glasses and zero logic.  Cognitive dissonance

How did you miss that those who bought CPH at $1 in 2011, made 1,400% in 2015 when it exceeded $15?


How did YOU miss that the stock went right back down to $1 after and ppl who held on lost 93.33% of their money?  Your statement is so absurd and such a cherry picking of the facts it's ridiculous.   Yeah, just omit the fact that the stock dropped right back down.  Very good, very objective presentation.  

Another
 lie you posted is that profitable debt-free CPH wrote off $5 million due to a dumb acquisition.

We're only at one lie so far, the one you presented in the paragraph above.  Now we we can work on your second lie.  

The fact is that CPH wrote off $5 million because CPH lost the lawsuit regarding Trulance, 
so it was not because of a dumb acqusition, facts below:

"The issue of whether Bausch Health is entitled to any additional amounts under the Agreement is deferred to a subsequent phase of the arbitration. As a result, the Company will impair approximately $5,400,000 USD in intangible assets related to upfront and milestone payments paid. "

You just proved my point... I mean like DUHHHH, they just wrote off 5.4 mil USD.  Do you think that amount got onto their balance sheet originally by magic?  Nope, they paid for it.  Now they are writing it off.  I guess we're up to lie #2... for you.  

Additionally, how did you miss that TRULANCE contributed ZERO revenue to CPH, so it has ZERO impact on CPH's top and bottom lines, facts below:


Didn't miss that at all.  They are writing off 5.4 mil USD for something they bought in the past and which is generating zero revenue.  Great purchase.  So, yeah, like you point out, the money they spent and totally wasted had to be writen off because it generated ZERO impact in earnings and ZERO revenues.  

I mean, like DUH.  I often wonder how some investors seem to have the logical capabilities of a housecat.  


I'm looking at this stock based on the possibilty that management will not repeat past errors of making bad acquisitions.  This is very hard because of the nature of the industry, and might not be entirely management's fault.  It must be difficult for them to find winners to back.  



<< Previous
Bullboard Posts
Next >>